Drugs / Cytokine Induced Killer (CIK) cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07709299 | Jul 2026 → Jul 2028 expected | hepatocellular carcinoma | Royan Institute | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01186809 | Jul 2009 → Sep 2016 | hematopoietic and lymphoid cell neoplasm | A.O. Ospedale Papa Giovanni XXIII | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cytokine-induced killer (CIK) cells | “called cytokine-induced killer (CIK) cells” NCT07709299 ↗ |
| Known as | CIK cells | “CIK cells have shown anti-leukemic activity and little graft-versus-host disease (GVHD) in several animal models.” PMID 17606446 ↗ Jul 20071“called cytokine-induced killer (CIK) cells” NCT07709299 ↗ |
| Action | Deplete | “CIK cells show strong cytotoxic activity against a variety of tumor target cell lines including B and T lymphomas and myeloid leukemias.” PMID 16980990 ↗ Sep 2006 |
| Modality | Cell therapy | “ex vivo-expanded autologous immune effector cells” NCT07709299 ↗ |
| Route | Intravenous | “six intravenous infusions of autologous CIK cells” NCT07709299 ↗ |